5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylic acid (1,3-dihydroxypropan-2-yloxy)amide | 1023742-29-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-acetyl-2-(2-fluoro-4-iodophenylamino)-1-methyl-1H-pyrrole-3-carboxylic acid (1,3-dihydroxypropan-2-yloxy)amide
• 英文别名: 5-Acetyl-n-(1,3-dihydroxypropan-2-yloxy)-2-(2-fluoro-4-iodophenylamino)-1-methyl-1h-pyrrole-3-carboxamide；5-acetyl-N-(1,3-dihydroxypropan-2-yloxy)-2-(2-fluoro-4-iodoanilino)-1-methylpyrrole-3-carboxamide
• CAS: 1023742-29-1
• 化学式: C₁₇H₁₉FIN₃O₅
• 分子量: 491.258
• InChiKey: RIMOLPWIINBFAW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  7

文献信息

• MAPK/ERK KINASE INHIBITORS
  申请人：Adams Mark E.

  公开号：US20080188453A1

  公开（公告）日：2008-08-07

  Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

  提供了用于MEK的化合物、药物组合物、试剂盒和方法，其中包括从以下群组中选择的化合物：其中变量的定义如本文所述。
• MAPK/ERK kinase inhibitors
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2113500A1

  公开（公告）日：2009-11-04

  Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound of formula: wherein the variables are as defined herein.

  本发明提供了用于 MEK 的化合物、药物组合物、试剂盒和方法，其中包含一种式化合物： 其中变量如本文所定义。
• METHOD OF REDUCING ADVERSE EFFECTS IN A CANCER PATIENT UNDREGOING TREATMENT WITH A MEK INHIBITOR
  申请人：THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV

  公开号：US20150265679A1

  公开（公告）日：2015-09-24

  What is described is a method for treating an adverse side effect of MEK inhibitors by administering a pharmaceutical composition comprising IFNγ to a cancer patient being treated by a MEK-inhibitor. The applicants discovered that MEK inhibitors produce unwanted visual disturbances as an adverse side effect in a significant fraction of cancer patients being treated by the drug, and that the side effect causes retinal detachment due to fluid accumulation in the eye. The method treats the retinal detachment caused by the anticancer therapeutic by providing a means of decreasing the amount of fluid present in the retina and/or subretinal space of the eye by administering the pharmaceutical composition comprising IFNγ to the basolateral side of the retinal pigment epithelium, preferably by administering the pharmaceutical composition to the anterior surface of the eye in liquid droplets.
• US7943659B2
  申请人：——

  公开号：US7943659B2

  公开（公告）日：2011-05-17
• [EN] MAPK/ERK KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE MAPK/ERK
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2008055236A2

  公开（公告）日：2008-05-08

  [EN] Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of ##STR## wherein the variables are as defined herein.
  [FR] L'invention concerne des composés, compositions pharmaceutique, kits et procédés pour utilisation avec MEK comprenant un composé sélectionné parmi le groupe composé de ##STR##, caractérisés en ce que les variables sont telles que définies dans la présente.